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caused by autosomal recessive loss-of-function mu-
tations in CYP27A1, a gene encoding cytochrome p450
oxidase essential for bile acid synthesis, resulting in
altered bile acid and lipid metabolism. Here, we
aimed to identify metabolic aberrations that drive
ongoing neurodegeneration in some patients with
CTX despite chenodeoxycholic acid (CDCA) supple-
mentation, the standard treatment in CTX. Using
chromatographic separation techniques coupled to
mass spectrometry, we analyzed 26 sterol metabolites
in serum and cerebrospinal fluid (CSF) of patients
with CTX and in one CTX brain. Comparing samples
of drug naive patients to patients treated with CDCA
and healthy controls, we identified 7α,12α-dihydrox-
ycholest-4-en-3-one as the most prominently elevated
metabolite in serum and CSF of drug naive patients.
CDCA treatment substantially reduced or even
normalized levels of all metabolites increased in un-
treated patients with CTX. Independent of CDCA
treatment, metabolites of the 27-hydroxylation
pathway were nearly absent in all patients with
CTX. 27-hydroxylated metabolites accounted for
∼45% of total free sterol content in CSF of healthy
controls but <2% in patients with CTX. Metabolic
changes in brain tissue corresponded well with find-
ings in CSF. Interestingly, 7α,12α-dihydroxycholest-4-
en-3-one and 5α-cholestanol did not exert toxicity in
neuronal cell culture. In conclusion, we propose
that increased 7α,12α-dihydroxycholest-4-en-3-one
and lack of 27-hydroxycholesterol may be highly
sensitive metabolic biomarkers of CTX. As CDCA
cannot reliably prevent disease progression despite
reduction of most accumulated metabolites, supple-
mentation of 27-hydroxylated bile acid intermediates
or replacement of CYP27A1 might be required to*For correspondence: Ludger Schöls, ludger.schoels@uni-tuebingen.
de; William J. Griffiths, w.j.griffiths@swansea.ac.uk.
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Cerebrotendinous xanthomatosis (CTX) is a neuro-
metabolic disease leading to progressive spastic-ataxic
gait disorder, cognitive decline, and frequently prema-
ture death due to abnormal bile acid and cholesterol
metabolism (1–3). It is caused by loss of function mu-
tations in CYP27A1 which is a key enzyme of bile acid
synthesis from cholesterol in the liver (4, 5). Lack of
CYP27A1 results in accumulation of abnormal lipids
including 5α-cholestanol which is widely used as a
diagnostic biomarker in CTX (6). Chenodeoxycholic
acid (CDCA) supplementation is established as a ther-
apy in CTX (7). It primarily reduces the production of
accumulated metabolites by end product inhibition of
expression mainly of cholesterol 7α-hydroxylase
(CYP7A1) (8), coding the rate-limiting enzyme of the
classical bile acid synthesis pathway, and is also shown
to often normalize serum levels of 5α-cholestanol (7, 9,
10). Despite this normalization of potentially neurotoxic
metabolites and reports of clinical improvement in
some patients after short-term treatment, many pa-
tients experience a progression of neurological deficits
in long-term follow-up, especially when treatment is
not initiated before neurological damage is apparent (9,
11, 12). To explore the metabolic background of neu-
rodegeneration in CTX, we used mass spectrometry to
perform in depth analyses of serum and cerebrospinal
fluid (CSF) of patients with CTX. By comparing bio-
samples of treated and untreated patients, we aimed toJ. Lipid Res. (2021) 62 100078 1
chemistry and Molecular Biology.
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TABLE 1. Clinical data of CTX patients included in this study and biosamples available for metabolic analyses
Age at Sampling Age of Onset Gender CYP27A1 Mutations Clinical Features
Pretreatment Posttreatment
Serum CSF Serum CSF
CTX 1 54 43 F c.379C>T, p.Arg127Trp
c.1016C>T, p.Thr339Met
Cognitive deficits, cerebellar ataxia - - X X
CTX 2 47 41 F c.379C>T, p.Arg127Trp
c.1016C>T, p.Thr339Met
Cataracts, cognitive deficits, cerebellar ataxia,
spastic tetraparesis
- - X X
CTX 3 45 43 F unknown Cataracts, cognitive deficits - - X -
CTX 4 61 30 F c.1183C>A, p.Arg395Ser hom Tendon xanthomas X X - -
CTX 5 47 10 M c.808C>T, p.Arg270*
c.1184+1G>A, p.?
Cognitive deficits, cataracts, depression,
polyneuropathy, cerebellar ataxia
X X X X
CTX 6a 60 n.d. M c.379C>T, p.Arg127Trp;
c.410G>A, p.Arg137Gln
Spastic paraparesis, tendon xanthomas X X - -
CTX 7 35 7 m M c.646G>C, p.Ala216Pro
c.1213C>T, p.Arg405Trp
Epilepsy, diarrhea, cognitive deficits,
cerebellar ataxia, spastic tetraparesis
X X - -
CTX 8a 29 26 F c.409C>T, p.Arg137Trp hom Tendon xanthomas X X - -
CTX 9 26 n.d. M unknown Large tendon xanthoma, cataracts,
ataxia, and cognitive deficits.
Brain autopsy
CO 1 61 - F - - X X - -
CO 2 45 - F - - X X - -
CO 3 53 - F - - X X - -
CO 4 46 - F - - X X - -
CO 5 32 - M - - X X - -
CO 6 57 - F - - X X - -
CO 7 53 - M - - X X - -
CO 8 27 - F - - X X - -
CO 9 48 - F - - X X - -
CO 10 30 - F - - X X - -
CO 11 56 - M - - Brain autopsy
CSF, cerebrospinal fluid; CTX, cerebrotendinous xanthomatosis; n.d., not determined.








identify metabolites that did not normalize upon CDCA
treatment and may drive continuous progression of the
disease. Metabolites that were highly elevated were
assessed for neurotoxic effects in a neuronal cell cul-
ture model.MATERIALS AND METHODS
Patient cohort
Patients with CTX were recruited from the leukodystro-
phy outpatient clinic of the University Hospital Tübingen,
Germany and the neurogenetics outpatient clinic at the
Friedrich-Baur-Institute, University Hospital, LMU Munich,
Germany, between 2011 and 2019. Biosamples were obtained
from nine patients with CTX including four patients
treated with 250 mg CDCA three times a day. Serum and
CSF of healthy control individuals without CTX (n = 10)
were provided by the Biobank of the Hertie Institute for
Clinical Brain Research, Tübingen, Germany. Controls CO
1–5 were used as reference for free metabolite determina-
tion; samples CO 6–10 served as controls for the assessment
of total amounts of cholesterol metabolites. Controls did not
differ concerning age and sex from the patient group.
Brain autopsy material derives from a male CTX patient
who died at 26 years of age as described in Battacharyya
et al. (13) (IRB00007099, Oregon Health and Science Uni-
versity). Brain material from a 56-year-old male without
neurological symptoms was kindly provided as a control by
the Thomas Willis Oxford Brain Bank with appropriate
research ethics approval (South Wales REC 13/WA/0292).
Biographic data and clinical features of all participants are
detailed in Table 1. Ethical approval for liquid biopsies was
given by the regulatory board of the Medical Faculty at the
University of Tübingen, Germany (vote 199/2011BO1). Par-
ticipants gave their written informed consent before in-
clusion in this study. The study was performed according to
the declaration of Helsinki principles.
Oxysterol analysis
Cholesterol and its downstream metabolites are mainly
present either in their free form, which is biologically active
or esterified to fatty acids for intracellular storage or
transport in lipoproteins. Sulfated and glucuronidated
forms are also found in serum and plasma. The usual
determination of total amounts in biological samples re-
quires a “harsh” saponification reaction to break the steryl
ester bonds, which can lead to unintended alterations in
molecule structures.
Therefore, we analyzed the free (nonesterified) fraction of
oxysterols in serum and CSF by employing a charge-tagging
approach using “enzyme-assisted derivatization for sterol
analysis” followed by liquid chromatography (LC) and elec-
trospray ionization mass spectrometry (MS) with multistage
fragmentation (MSn) as previously described (14–16). In brief,
oxysterols and C27 acids were separated from cholesterol and
other hydrophobic sterols by solid phase extraction. The
resulting oxysterol fraction was divided into two equal ali-
quots A and B. Fraction A was first oxidized using cholesterol
oxidase and then derivatized with [2H5]Girard P reagent,
whereas fraction B was derivatized with [2H0] Girard P re-
agent in the absence of cholesterol oxidase treatment. Using
this approach, we were able to differentiate between metab-
olites that are either in a 3-oxo-4-ene form (Fraction B) or inthe 3β-hydroxy-5-ene form (Fraction A minus Fraction B). To
allow for simultaneous detection of both forms, immediately
before LC-MSn the two fractions were combined. A detailed
analysis scheme including exact masses, retention times and
fragmentation spectra can be found in Griffiths et al. (17).
Oxysterols in brain were analyzed using a similar approach as
described in the same reference.
As detection of 5α-cholestanol in serum and CSF was not
possible with LC-MS because of masking of the signal by
excess cholesterol (18), we used gas chromatographic separa-
tion to determine total amounts (nonesterified plus esterified)
of cholesterol, 5α-cholestanol, 7α-hydroxycholesterol (7α-HC),
and 27-hydroxycholesterol (27-HC) as described before (19).
Note that the systematic name for 27-HC is (25R)26-
hydroxycholesterol (cholest-5-ene-3β,(25R)26-diol); however,
as 27-HC is more commonly used, it will be adopted
throughout the manuscript. For some metabolites, we were
able to discriminate between (25R)26- and (25S)26-
hydroxylated or carboxylated stereoisomers. For simplicity,
only the latter were explicitly stated.
Toxicity assays
Mouse motor neuron-like hybrid cell line (NSC-34) cells
were cultured in T-75 flasks (Corning) in DMEM/F12 medium
supplemented with 10% fetal bovine serum (FBS, Gibco) and
routinely passaged at ∼80–90% confluency using Trypsin/
EDTA (Merck).
For cytotoxicity assays, 7,500 cells/well were seeded in
black-walled CellCarier 96-well plates (PerkinElmer) coated
with a 1:60 dilution of growth factor reduced Matrigel
(Corning). Cells were cultivated for 3 days in DMEM/F12 +
10% FBS. Afterwards, FBS was withdrawn from the medium
to induce differentiation for 4 days. Then, serial dilutions of
7α,12α-dihydroxycholest-4-en-3-one (TRC), 5α-cholestanol,
and 27-HC (Avanti Polar lipids) were freshly prepared in
DMEM/F12 from a stock solution of 12.5 mM (solved in EtOH)
to yield final concentrations of 0.2 μM, 1 μM, 5 μM, 25 μM, and
100 μM and applied to the cells for 4 days without media
change in between.
Cell proliferation reagent WST-1 (Roche) and LDH-Glo™
Cytotoxicity Assay (Promega) were performed according to
the manufacturer’s guidelines, and absorption or lumines-
cence were measured after 1 h of incubation on a SpectraMax
M2e Microplate Reader (Molecular Devices).
Statistics
For statistical analysis of the oxysterol and sterol, concen-
trations data were log-transformed using the following
equation: f (x) = log 10(x + 1̅2̅√ ) with 1̅2̅√ added to prevent log
values of 0. For each metabolite, normal distribution was
assumed when absolute values for skewness and kurtosis were
below 1. Equality of variances was assessed using Levene’s test
(α = 0.05). If a data set passed both tests, it was further
analyzed by one-way ANOVA, and pairwise comparisons
were calculated with the least significant difference test,
otherwise the nonparametric Kruskal-Wallis test followed by
Mann-Whitney U tests was used. Data were Bonferroni cor-
rected with m = 4 for the four primary pathways (7α-hy-
droxylation, 24-hydroxylation, 25-hydroxylation, and 27-
hydroxylation) analyzed in this study assuming that
different metabolites belonging to the same pathway are not
independent variables. Significance was assumed for P <
0.0125. The data were analyzed using SPSS.Metabolic profiling of patients with CTX 3
RESULTS
Cholesterol
As cholesterol is the biosynthetic precursor of all
primary bile acids (Fig. 1), we compared total choles-
terol levels measured by GC-MS in the three groups
(healthy controls, drug-naive CTX patients, and CDCA-
treated patients with CTX). There were no significant
differences in the amount of total cholesterol in serum
(Table 2). In CSF, the mean total cholesterol concen-
tration in untreated patients with CTX was 2-fold
higher compared with controls, but the difference
was not statistically significant (Fig. 2A, Table 3).
7α-hydroxylation pathway
The classical CYP7A1-related pathway accounts for
∼90% of total bile acid synthesis and is initiated by 7α-
hydroxylation of cholesterol (Fig. 1) (20). Total serum
levels of 7α-HC as assessed by GC-MS were increased
14-fold in untreated patients with CTX compared with
healthy controls (P < 0.0125, Fig. 2B), whereas the con-
centration of the free fraction of 7α-HC as determined
by LC-MS was comparable between groups (Fig. 3A).
However, the 3-oxo form, 7α-hydroxycholest-4-en-3-
one (7α-HCO, also known by the trivial name C4 or
7α-C4), was elevated two orders of magnitude in serum
of patients with untreated CTX (P < 0.0125, Fig. 3B,
Table 2). Total 5α-cholestanol, the most commonly used
diagnostic biomarker in CTX, was on average ∼10-foldFig. 1. Overview of bile acid synthesis pathways. Important interm
route of cholesterol catabolism in the liver are displayed on the lef
acidic pathway initiated by CYP27A1 (expressed in many tissues incl
expressed in brain), and the 25-hydroxylation pathway (CH25H) are
CTX, are highlighted by red lettering of CYP27A1. Reactions cataly
CTX, are highlighted by green lettering. Red arrowheads (signific
ferences measured in patients with CTX in relation to controls in ser
CSF. Only metabolites with symbols were analyzed. CSF, cerebrosp
4 J. Lipid Res. (2021) 62 100078elevated in serum and CSF, measured by GC-MS, but
two patients showed 5α-cholestanol levels only slightly
above control values (marked by red squares in Fig. 2C).
Interestingly, these two patients had also the lowest
amounts of 7α-HCO in serum and 7α-HC in CSF as
measured by LC-MS (Fig. 3A, B).
The 12α-hydroxylated downstreammetabolite 7α,12α-
dihydroxycholest-4-en-3-one (7α,12α-diHCO) turned
out to be the most highly elevated compound in our
data set even in the two patients with almost normal 5α-
cholestanol, 7α-HC, and/or 7α-HCO values (Fig. 3C),
with mean levels about 11,000-fold higher in untreated
patients with CTX compared with controls (1614.9 ng/
ml [range: 49.21–4602.03] vs. 0.16 ng/ml [range:
0.02–0.38]; P < 0.0125). In CSF, the mean concentration
of 7α,12α-diHCO was 350-fold higher in untreated pa-
tients with CTX compared with controls (8.76 ng/ml
[range 0.32–31.97] vs. 0.03 ng/ml [range: 0–0.08], P <
0.0125, Fig. 3C). A similar pattern was found for 12α-
hydroxycholesta-4,6-dien-3-one, the dehydration prod-
uct of 7α,12α-diHCO (Fig. 3D, Table 3).
27-Hydroxylation pathway
The 27-hydroxylation pathway is depicted in Fig. 1.
Owing to mutations in CYP27A1, the synthesis of 27-
HC, 3β-hydroxycholestenoic acid, and other down-
stream metabolites of the alternative pathway of bile
acid synthesis are absent (below the limit of detection/
quantification) in patients with CTX (Fig. 3E–H). Ofediates of the classical pathway of bile acid synthesis as the main
t. Next to it, intermediates of alternate pathways including the
uding the lung and brain), the cerebral pathway (CYP46A1; only
shown. Reactions catalyzed by CYP27A1, the enzyme lacking in
zed by CYP7A1 and CYP8B1, the main enzymes upregulated in
antly increased/decreased) and bars (unchanged) indicate dif-
um. Blue arrowheads exhibit differences between the groups in
inal fluid; CTX, cerebrotendinous xanthomatosis.
TABLE 2. Sterol concentrations in serum
Systematic Name Common Name (Abbreviation)
Control (n = 5) CTX (n = 5) CDCA (n = 4)
NoteMean Range Mean Range Mean Range
GC-MS
Total cholest-5-en-3β-ol Total cholesterol 1.86 mg/ml 1.53–2.66 2.07 mg/ml 1.08–2.55 1.34 mg/ml 1.12–1.60
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Cholest-5-ene-3β,25-diol 25-Hydroxycholesterol
(25-HC)







































0.34 0.17–0.47 33.38 4.1–53.55 1.89 1.05–2.9 a,d,e





55.00 44.13–64.22 0.00 - 0.00 - a,b,d
3-Oxocholest-4-en-(25R)
26-oic acid
3-Oxocholestenoic acid 1.04 0.58–1.47 0.00 - 0.00 - a,b,d



























































0.20 0.07–0.41 0.00 - 0.00 - a,b,d
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TABLE 2. Continued
Systematic Name Common Name (Abbreviation)
Control (n = 5) CTX (n = 5) CDCA (n = 4)







dienoic acid and/or 3β-
Hydroxycholesta-5,Y-dien-
26-oic acid
1.59 0.15–2.72 0.44 0.00–1.85 0.00 - d
3-Oxocholesta-4,6-dien-












0.45 0.00–0.78 306.98 35.63–636.95 11.45 2.34–19 a,b,c
24 or 25-
Hydroxycholesta-4,6-




4,6-dien-3-one and/or 24 or
25-Hydroxycholesta-4,8-
dien-3-one
0.26 0.12–0.48 1.6 0.72–2.13 0.77 0.63–0.95 d,e,h
CDCA, chenodeoxycholic acid; CTX, cerebrotendinous xanthomatosis.
CTX group: Patients CTX 4–8, CDCA group: Patients CTX 1–3 and CTX 5
aP < 0.0125 for comparison between controls and untreated patients with CTX.
bP < 0.0125 for comparison between controls and patients with CTX treated with 750 mg/day CDCA.
cP < 0.0125 for comparison between drug-naive and CDCA-treated patients with CTX.
dValues below limit of quantification of 0.1 ng/ml in CSF or 0.5 ng/ml in serum.
eIdentification based on exact mass retention time and MS3 spectrum in the absence of an authentic standard.
fMS3 spectra do not allow the differentiation between the isomers/epimers.
gThe position of the additional hydroxy group is not determined.
hIn CTX, there is no direct synthesis of (25R)26-oic acids and most likely a 25-hydroxy-3,24-dione structure is present.interest, 3β,7α-dihydroxycholestenoic acid, previously
shown to be neuroprotective (21), was completely lack-
ing in serum of the CTX group (Fig. 3G), as well as itsFig. 2. Total levels of key metabolic markers of cerebrotendinou
metabolites measured by GC-MS in serum (upper panel) and CSF
(CTX, red) and patients treated with 750 mg/day CDCA (CDCA, blu
SD on a logarithmic scale with antilog numbering. Absolute values o
highlight patients with CTX with low cholestanol levels and triangula
after CDCA treatment. *P < 0.0125 calculated by one-way ANOVA a
* are only indicated for significant pair-wise comparisons. CDCA, c
6 J. Lipid Res. (2021) 62 100078downstream metabolite 7α-hydroxy-3-oxocholestenoic
acid (Fig. 3H), one of the main oxysterols exported
from brain which was not detectable in patients’ serums xanthomatosis (CTX). A–D: Concentrations of the indicated
(lower panel) of controls (green), untreated patients with CTX
e). The data are presented as individual data points and mean ±
f zero correspond to log-values of ∼0.7. Square-shaped data points
r points highlight the patient we obtained data from before and
nd Fisher’s LSD or by Kruskal-Wallis and Mann-Whitney-U tests.
henodeoxycholic acid; CSF, cerebrospinal fluid.
TABLE 3. Sterol concentrations in cerebrospinal fluid (CSF)
Systematic Name Common Name (Abbreviation)
Control (n = 5) CTX (n = 5) CDCA (n = 3)
NoteMean Range Mean Range Mean Range
GC-MS
Total cholest-5-en-3β-ol Total cholesterol 2.4 μg/ml 1.5–3.3 5.6 μg/ml 2.1–7.5 4.5 μg/ml 4.1–4.7










1.23 ng/ml 0.73–1.94 0 - 0 - a
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Cholest-5-ene-3β,25-diol 25-Hydroxycholesterol
(25-HC)





































0.11 0.07–0.23 0.43 0.17–0.86 0.05 0.00–0.1 a,c,d,e





0.61 0.41–0.87 0.00 - 0.01 0.00–0.02 a,d
3-Oxocholest-4-en-(25R)
26-oic acid
3-Oxocholestenoic acid 0.00 - 0.00 - 0.00 - d



























































0.76 0.49–1.6 0.00 - 0.00 - a,d,f
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TABLE 3. Continued
Systematic Name Common Name (Abbreviation)
Control (n = 5) CTX (n = 5) CDCA (n = 3)







dienoic acid and/or 3β-
Hydroxycholesta-5,Y-dien-
26-oic acid
0.00 - 0.00 - 0.00 - d
3-Oxocholesta-4,6-dien-












0.00 - 4.59 0.54–11.97 0.00 - a,d
24 or 25-
Hydroxycholesta-4,6-




4,6-dien-3-one and/or 24 or
25-Hydroxycholesta-4,8-
dien-3-one
0.00 - 0.00 - 0.00 - d
CTX, cerebrotendinous xanthomatosis; CDCA, chenodeoxycholic acid.
CTX group: Patients CTX 4–8, CDCA group: Patients CTX 1, CTX 2, and CTX 5
aP < 0.0125 for comparison between controls and untreated patients with CTX.
bP < 0.0125 for comparison between controls and patients with CTX treated with 750 mg/day CDCA.
cP < 0.0125 for comparison between drug-naive and CDCA-treated patients with CTX.
dValues below limit of quantification of 0.1 ng/ml in CSF or 0.5 ng/ml in serum.
eIdentification based on exact mass retention time and MS3 spectrum in the absence of an authentic standard.
fMS3 spectra do not allow the differentiation between the isomers/epimers.
gThe position of the additional hydroxy group is not determined.
hIn CTX, there is no direct synthesis of (25R)26-oic acids and most likely a 25-hydroxy-3,24-dione structure is present.and CSF (22). Note that unless stated otherwise, these
metabolites have 25R-stereochemistry.
24S-hydroxylation pathway
The cerebral pathway of bile acid synthesis is initi-
ated by the 24S-hydroxylation of cholesterol by
CYP46A1 (only expressed in brain tissue). In parallel,
24S-hydroxylation provides the major route for
cholesterol removal from the brain (Fig. 1). 7α,24S-
Dihydroxycholestenone and its dehydration product
24S-hydroxycholesta-4,6-dien-3-one were increased in
serum of untreated patients with CTX (P < 0.0125,
Table 2). The abovementioned metabolites were not
detectable in CSF. Whereas 24S-hydroxycholesterol was
unchanged, and 7α,24-dihydroxy-3-oxocholestenoic
acid was reduced in CSF of the CTX group (P <
0.0125; Table 3).
25-hydroxylation pathway
The 25-hydroxylation pathway (Fig. 1) is responsible
for only about 1–2% of bile acid production, at least in
rat (23). Nevertheless, the concentrations of 7α,25-
dihydroxycholest-4-en-3-one (7α,25-diHCO) and
7α,12α,25-trihydroxycholest-4-en-3-one were highly
elevated about 9 to 30-fold in serum of untreated pa-
tients compared to controls (P < 0.0125, Table 2). Both
metabolites are precursors of 25-hydroxylated bile al-
cohols that are established as biomarkers for CTX in
blood, feces, and urine (24, 25). In CSF, the levels of
these molecules are much lower compared with serum,
and 7α,25-diHCO was not detectable in controls, but
both metabolites were significantly elevated about 10-8 J. Lipid Res. (2021) 62 100078fold to 20-fold above the detection limit in CTX (P <
0.0125, Table 3). A detailed overview of all analyzed
metabolites depicted in Fig. 1 is provided in Tables 2
and 3 for serum and CSF, respectively.
Sterol distribution in CTX and control brain
To compare biochemical findings in serum and CSF
with concentrations in the brain, we assessed the oxy-
sterol composition in the cerebrum, cerebellum, me-
dulla oblongata, substantia nigra, and basal ganglia
from an autopsy case with CTX and cerebrum from a
control brain (Table 4, Fig. 4A). The patient with CTX
was not treated with CDCA before death. Because of
low concentrations of some of the analyzed metabo-
lites, the brain levels of the respective cholest-5-en-3β-ol
(HC) and cholest-4-en-3-one (HCO) forms were com-
bined for Fig. 4A and abbreviated as HC(O). A separate
listing of the two forms can be found in Table 4. After
normalization for cholesterol levels to correct for dif-
ferences in sample conditions, the mean concentration
of 7α-HC(O) was more than 60-fold increased in CTX
brain compared with control brain (Fig. 4A). The me-
tabolites 7α,12α-diHC(O) and 25-HC(O) were not detec-
ted in control brain but were present in the CTX brain
(Fig. 4A). Similarly, 5α-cholestanol was ascertainable
only in the CTX brain. In contrast, 27-HC was only
found in control brain. The concentration of 24S-
hydroxycholesterol was comparable in control and
CTX brain (Fig. 4A). In the CTX brain, levels of all
metabolites were similar in cerebrum compared with
medulla oblongata, substantia nigra, basal ganglia, and
a cerebellar xanthoma. (Fig. 4A).
Fig. 3. Analysis of metabolites of the classical CYP7A1-dependent pathway and of the alternative CYP27A1-dependent pathway for
bile acid synthesis. A–H: Serum concentrations of free oxysterols measured by LC-ESI-MS are presented in the upper panel and CSF
findings in the lower panel. Healthy controls are indicated in green, untreated patients with CTX in red and patients treated with
750 mg/d CDCA in blue. Individual data points and mean ± SD are presented on a logarithmic scale with antilog numbering.
Absolute values of zero correspond to log-values of ∼0.7. Square-shaped data points highlight patients with CTX with low cholestanol
levels and triangular points highlight the patient we obtained data from before and after CDCA treatment. *P < 0.0125 calculated by
one-way ANOVA and Fisher’s LSD or by Kruskal-Wallis and Mann-Whitney-U tests. * are only indicated for significant pair-wise
comparisons. CDCA, chenodeoxycholic acid; CTX, cerebrotendinous xanthomatosis.Toxicity of 7α,12α-dihydroxycholest-4-en-3-one and
5α-cholestanol in cell culture
To explore potential detrimental effects of the
two most abundant abnormal oxysterols in CTX, we
performed WST-1 cleavage and lactate dehydroge-
nase (LDH) release assays in neuronal NSC-34 cells.
In addition to 7α,12α-diHCO and 5α-cholestanol, 27-
HC was included in toxicity assessments as apositive control metabolite that has previously been
shown to be neurotoxic (26). As expected, the
addition of 27-HC was associated with dose-
dependent decreases in WST-1 cleavage and in-
creases in LDH release, with IC-50 values of 1.2 μM
and 72.7 μM, respectively (Fig. 4B, C). In contrast, the
addition of 7α,12α-diHCO and 5α-cholestanol did not
change WST-1 cleavage or LDH release up toMetabolic profiling of patients with CTX 9
TABLE 4. Sterol concentrations in different brain regions of one control and one CTX patient
Common Name Abbreviation
Control CTX
Cerebrum Cerebrum Medulla Oblongata Cerebellar Xanthoma Substantia Nigra Basal Ganglia
24S-Hydroxycholesterol 24S-HC 1.31 1.63 0.73 1.35 0.95 2.43
25-Hydroxycholesterol 25-HC 0.00 0.06 n.m. n.m. n.m. n.m.
25-Hydroxycholestenone 25-HCO 0.00 0.01 n.m. n.m. n.m. n.m.
25-HC+25-HCO 0.00 0.06 0.08 0.11 0.06 0.24
7α-Hydroxycholesterol 7α-HC 0.03 1.35 1.41 2.86 1.18 3.81
7α-Hydroxycholestenone 7α-HCO 0.00 0.34 0.45 0.40 0.45 0.40
7α-HC+7α-HCO 0.03 1.70 1.87 3.26 1.63 4.20
27-Hydroxycholesterol 27-HC 0.11 0.00 0.00 0.00 0.00 0.00
7α,12α-Dihydroxycholesterol 7α,12α-HC 0.00 0.08 0.01 0.02 0.01 0.00
7α,12α-
Dihydroxycholestenone
7α,12α-HCO 0.00 0.19 0.14 0.11 0.11 0.18
7α,12α-HC+7α,12α-
HCO
0.00 0.27 0.15 0.13 0.13 0.18
5α-Cholestanol 5α-Cholestanol 0.00 4.56 2.29 1.07 0.87 1.05
All values in ng/μg cholesterol and for free oxysterols measured by LC-MS.
CTX, cerebrotendinous xanthomatosis; n.m., not measured.concentrations three orders of magnitude above
levels found in CSF of patients with CTX.
CDCA effects on abnormal metabolites
To determine the metabolic effects of CDCA treat-
ment, we analyzed sterols in serum and CSF of patients
with CTX under supplementation therapy with CDCA
(750 mg/day) for at least 8 months. We found CDCA to
largely normalize the elevated levels of total 5α-cho-
lestanol (Fig. 2C) and total 7α-HC in serum as well as in
CSF (Fig. 2B), whereas it had no effect on total choles-
terol levels (Fig. 2A). Concerning free 7α,12α-diHCO, the
most extensively elevated metabolite in our analysis,
CDCA treatment lowered the mean serum levels
significantly from 1614.9 ng/ml (range: 49.21–4602.03)
to 35.64 ng/ml (range: 3.44–50.07) (P < 0.0125), whereas
mean levels were still 220-fold increased compared with
controls (P < 0.0125, Fig. 3C). In CSF, CDCA supple-
mentation reduced the mean levels of 7α,12α-diHCO
from 8.76 ng/ml (range: 0.32–31.97) to 0.13 ng/ml
(range: 0.1–0.15). Most other metabolites of the 7α-, 24S-
and 25-hydroxylation pathways that were elevated in
CTX were reduced to almost normal levels with CDCA
treatment (for details see Table 2). In CSF, only the two
metabolites 7α-HCO and 7α,25-diHCO were still signif-
icantly increased compared to controls after CDCA
treatment although with very low absolute concentra-
tions (Table 3). No effect of CDCA treatment was seen
on metabolites of the 27-hydroxylation pathway. 27-
Hydroxylated metabolites remained absent in serum
and CSF upon treatment.
Overall levels of oxysterols
In total, seven metabolites in the free sterol fraction
were significantly increased in serum of untreated pa-
tients with CTX compared with controls. On the other
hand, eight metabolites were decreased, and nine me-
tabolites were similar to controls (Table 2).10 J. Lipid Res. (2021) 62 100078To compare total amounts of oxysterols present in
the different samples, mean concentrations of all 24
metabolites determined by LC-MS in the free sterol
fraction were assigned to the respective pathways as
depicted in Fig. 1 (Fig. 4D–H). By this analysis, we found
total serum oxysterols to be drastically increased from
154.55 ng/ml (range: 145.38–170.44) in controls to
2265.95 ng/ml (range: 217.76–5725.68) in untreated pa-
tients with CTX (Fig. 4D). Especially the 7α-hydroxyl-
ation pathway contributed to this increase, comprising
36% of total oxysterols in controls and 96% in the CTX
group (Fig. 4E). More specifically, the two metabolites
7α,12α-diHCO and 12α-hydroxycholesta-4,6-dien-3-one
alone were responsible for 90% of the difference.
While the mean total amount of metabolites belonging
to the 24S- and 25-hydroxylation pathways were only
slightly increased compared with controls the 27-
hydroxylation pathway was heavily reduced from
120.45 ng/ml (range: 110.55–143) in controls to only
7.86 ng/ml (range: 0.10–24.03) in drug-naive patients
with CTX which corresponds to 0.34% of total oxy-
sterols. CDCA treatment reduced mean total oxysterols
in serum of patients with CTX to 89.49 ng/ml (range:
39.59–115.4) because of a normalization of the 7α-, 24S
and 25-hydroxylation pathways (Fig. 4E–G). However,
metabolites of the 27-hydroxylation pathway were still
absent (Fig. 4H).
The relative contribution of the different pathways
to total oxysterol levels was similar in serum and CSF in
controls, although the overall levels were much lower in
CSF (Fig. 4D).
In CSF, we could only detect 17 metabolites. Of these,
the five metabolites with increased levels in the CTX
group were all found in the 7α- and the 25-
hydroxylation pathways, whereas seven metabolites of
the 27-hydroxylation pathway were almost absent
(Fig. 4E, F, H). Metabolites of the 24S-hydroxylation
pathway were slightly reduced. Upon CDCA treatment,
overall oxysterol levels in CSF were drastically reduced
Fig. 4. Sterol composition of brain, toxicity of CTX-related metabolites, and overall oxysterol composition. A: Oxysterol content
(free, nonesterified) as measured by LC-ESI-MS of brain autopsies of an untreated CTX patient (red) and a control (green). Data are
normalized to cholesterol content. B: WST-1 assay and (C) LDH release assay of NSC-34 cells treated with increasing concentrations
(0.2 μM, 1 μM, 5 μM, 25 μM, and 100 μM) of the indicated sterol metabolites. N = 3–6. D: Sum of all oxysterols and (E–H) the individual
pathways measured by LC-ESI-MS in serum (upper panel) and CSF (lower panel) of controls (green), untreated patients with CTX
(red) and patients treated with 750 mg/day CDCA (blue). Individual data points and mean ± SD are presented on a logarithmic scale
with antilog numbering. Absolute values of zero correspond to log values of ∼0.7. Square-shaped data points highlight patients with
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to only 2.09 ng/ml (range: 0.58–4.89) and even 90%
lower than in controls (Fig. 4D). Thereby, both, metab-
olites of the 7α- and the 27-hydroxylation pathway were
greatly reduced or almost absent with only 0.48 ng/ml
(range: 0.34–0.66) and 0.04 ng/ml (range: 0.02–0.08),
respectively (Fig. 4E, H).DISCUSSION
In this comprehensive analysis of lipid metabolites in
CTX and controls, GC-MS and LC-MS were used to
quantify 26 metabolites in serum and CSF from drug
naive and CDCA-treated patients with CTX. These an-
alyses revealed a dichotomic pattern with metabolites in
the 7α- and 25-hydroxylation pathways being increased
in CTX, whereas 27-hydroxylated and carboxylated
cholesterol products were largely lacking. This finding
is in good accordance with results from published
studies (2, 17, 27) and generally applies to both serum
and CSF, though with substantial differences in the
concentration and composition of oxysterols between
serum and CSF.
We further compared serum and CSF findings with
the oxysterol profile in brain. Mass spectrometry anal-
ysis of a CTX brain confirmed oxysterol alterations
that were similar to changes observed in CSF. The
metabolites 25-hydroxycholesterol and 7α,12α-diHC(O)
were absent in both CSF and cerebrum of controls,
whereas they were detectable in CSF and brain of pa-
tients with CTX (Figs. 3C, 4A, Tables 3 and 4). Moreover,
levels of 7α-HC(O) were highly increased in CSF and
brain from patients with CTX (Figs. 2B, 3A, B, 4A),
whereas 27-HC was only detectable in controls (Figs. 2D,
3E, 4A). The highly elevated 7α-HC(O) in brain of an
untreated CTX patient is in accordance with the pro-
posed mechanism of cerebral accumulation of 5α-cho-
lestanol in CTX via flux of 7α-HC(O) across the blood-
brain barrier into the brain in a CTX mouse model and
subsequent conversion to 5α-cholestanol (28). It is
noteworthy that CYP7A1, the enzyme that introduces
the 7α-hydroxy group to cholesterol and sterol 12α-hy-
droxylase (CYP8B1) which is responsible for 12α-hy-
droxylation are liver specific and not expressed in
brain (data available from v20.1.proteinatlas.org) (29).
Hence, the identification of these metabolites in brain
most likely reflects uptake from the circulation by
crossing the blood-brain barrier or alternatively via
nonenzymatic free radical oxidation reactions. Our
study proves that key metabolic changes observed in
brain tissue were also identified in CSF and serum of
CTX patients and suggest that both, CSF and serum, are
suitable for monitoring the effects of therapeutic ap-
proaches in CTX.CTX with low cholestanol levels and triangular points highlight th
ment. One-way ANOVA and Fisher’s LSD or Kruskal-Wallis and M
significance.
12 J. Lipid Res. (2021) 62 1000787α,12α-diHCO, 5α-cholestanol, and 7α-HC(O) were
identified as the most abundant oxysterols in CTX with
markedly increased levels in both serum and CSF. It has
been hypothesized that increased levels of these me-
tabolites in CSF and brain may contribute to neuro-
degeneration in patients with CTX. In our neuronal cell
culture toxicity study, no toxic effect was identified for
7α,12α-diHCO and 5α-cholestanol in contrast to 27-HC
at concentrations up to three orders of magnitude
higher than levels found in CSF of patients (Fig. 4B, C).
These results suggest no direct contribution of the
tested compounds to neurotoxicity in CTX. Neverthe-
less, long-term exposure to neuronal cells may produce
toxicity that would not be identified in our cell culture
system. This possibility is in line with the observation
that neurodegenerative complications from CTX typi-
cally develop slowly over decades. Moreover, it is
possible that other cell types in the brain may be
adversely affected by chronically elevated levels of
oxysterols, leading to neurodegeneration.
In CTX, reduced amounts of bile acids and possibly
bile alcohols induce a feedback mechanism mediated
by farnesoid X receptor leading to upregulation of
enzymes involved in bile acid synthesis including
CYP7A1 and CYP8B1 (30). This leads to increased pro-
duction of oxysterols that normally require 27-
hydroxylation to be further processed into bile acids.
As most CYP27A1 mutations cause an almost complete
lack of sterol 27-hydroxylase, these metabolites and 5α-
cholestanol accumulate in tissues resulting in tendon
xanthomas, early onset cataracts, and cerebellar lipid
deposits.
CDCA is established as an efficacious treatment for
CTX that suppresses CYP7A1 and CYP8B1 activity to
almost normal levels (31). In our study, this is reflected
by the marked reduction or normalization after CDCA
therapy of most metabolites which are elevated in un-
treated patients with CTX. For example, the overall
oxysterol serum levels were elevated 10-fold in un-
treated patients with CTX compared with controls
(2447 ng/ml vs. 207 ng/ml) but normalized to 163 ng/
ml after CDCA treatment. In contrast, in CSF, the
overall oxysterol levels were not increased in CTX, but
their composition was altered. The CDCA treatment
reduced the total levels of oxysterols in CSF far below
controls. This is driven by the lack of 27-hydroxylated
metabolites which constitute 45% of free sterols in
CSF of healthy.
Consistent with results from earlier studies (6, 21),
CDCA treatment did not alleviate impairment in the 27-
hydroxylation pathway in CTX, resulting in severe lack
of related metabolites like 27-HC, 3β-hydrox-
ycholestenoic acid, and 3β,7α-diHCA. While 27-HC ise patient we obtained data from before and after CDCA treat-
ann-Whitney-U tests were performed and showed no statistical
the main metabolite imported from the circulation into
the brain (32), 7α-hydroxy-3-oxocholestenoic acid
together with 24S-hydroxycholesterol are the main
export products (22). 27-HC has been reported to be a
regulator of brain cholesterol synthesis and homeosta-
sis mediated by its binding to nuclear liver X receptors
and INSIG proteins (33, 34). Furthermore, 27-HC has
been shown to potentially foster neuronal cholesterol
efflux by increasing expression of the ABC trans-
porters ABCA1, ABCG5, and ABCG8 and APOE (35).
This suggests that the lack of CYP27A1 activity in CTX
adversely affects both the import of cholesterol me-
tabolites into the brain as well as a route for cholesterol
removal. The lack of 27-HC may further stimulate
cholesterol synthesis in the brain, which might increase
the tendency to accumulate cholesterol and 5α-choles-
tanol in brain xanthomas. In addition, we have previ-
ously shown that the CYP27A1 metabolite 3β,7α-diHCA
which is strongly reduced in CTX increases motor
neuron survival and facilitates maturation into islet-1+
cells in a liver X receptors–dependent manner (21).
Hence, the lack of these 27-hydroxylated and carbox-
ylated metabolites in the brain of patients with CTX
may play a critical role in neurodegenerative processes.
Taken together, there is strong evidence that
impairment of the 27-hydroxylation pathway may have
a crucial role in the pathogenesis of neurodegeneration
in CTX. Although treatment with CDCA normalizes the
levels of metabolites such as 5α-cholestanol in plasma
and seems to be beneficial when treatment is started
early in the course of CTX, many patients show pro-
gressive neurodegeneration in the long term. Such pa-
tients may benefit from treatment that improves sterol
27-hydroxylation. A potential strategy is the replace-
ment of defective CYP27A1. In principle, this could be
achieved either by direct enzyme replacement, liver
transplantation, supplementation of CYP27A1 mRNA
via nanoparticles, or by hepatocyte-specific viral vectors
transferring a wildtype gene copy. Further studies are
needed to determine the efficacy of these liver
centered strategies in the brain. Treatment with adeno-
associated viruses to target disease-relevant genes
directly in the brain could be another option. Currently,
several phase I/II experimental clinical trials for
treatment of other neurodegenerative diseases such as
Alzheimer’s disease, Parkinson’s disease, or spinal
muscular atrophy with this method are ongoing (36).
From a diagnostic point of view, our results challenge
the notion of 5α-cholestanol as the primary diagnostic
biomarker for CTX. Previously, it has been shown that
other diseases like familial hypercholesterolemia and
sitosterolemia also present with increased levels of 5α-
cholestanol (37). Although the diagnosis of CTX is now
primarily genetically based, there are still variants of
unknown significance on the one hand and mutations
that are difficult to detect like deep intronic splice
variants on the other hand that require metabolic
confirmation to reach a definite diagnosis, historicallyperformed by measuring 5α-cholestanol levels. In our
series, we found two patients with only marginal in-
creases in 5α-cholestanol levels compared with controls.
Hence, we recommend using the increase in 7α,12α-
diHCO and the lack of 27-HC or their ratio as primary
diagnostic biomarkers in CTX as proposed in prior
publications (37, 38). In addition, it is important to assess
the oxysterol metabolism in CTX after diagnosis to
ensure treatment efficacy. This study suggests to
monitor apart from 5α-cholestanol other biomarkers
like free 7α-HCO or 7α,12α-diHCO which may consti-
tute more sensitive markers of sufficient suppression of
the classical CYP7A1-initiated pathway and do not re-
turn to normal levels with CDCA treatment (Fig. 3B, C).
Early diagnosis and treatment appear to be of major
importance according to the study of Stelten et al. (12)
who found favorable responses when CDCA treatment
started before the age of 24 years. In our study, treat-
ment started late (between 45 and 60 years of age) and
only after cognitive decline in all patients and after the
development of additional neurological symptoms
including cerebellar ataxia in three-fourths patients.
Although it would be interesting to investigate the
metabolic profile in patients who have been treated
since young age and show favorable courses of the
disease in response to CDCA treatment, we do not
expect major metabolic differences in this group
compared with the patients in later stages included in
our study. All metabolites accumulating in CTX do
almost normalize in serum and CSF with CDCA treat-
ment also in late stages and metabolites that are missing
in CTX because of a lack of 27-hydroxylation cannot
be substituted independent how early CDCA treatment
is started. However, early treatment may prevent
deposition of large amounts of abnormal lipids in the
brain that are potentially insoluble, especially in late
stages of the disease.
There are several limitations of our study. Despite
the extensive metabolic analyses performed in this
study, there are other known sterol metabolites that
could not be assessed by the mass spectrometric tech-
niques applied in this study. These include bile alcohols
that could not be detected by LC-MS, without polarity
switching, in serum and CSF, but are known to be
substantially increased in plasma, feces, and urine of
CTX patients (39). However, the bile alcohol precursor
7α,12α,25-trihydroxycholest-4-en-3-one was elevated in
serum and CSF of untreated patients with CTX. After
CDCA treatment, the levels were reduced in both
specimens (Tables 2 and 3).
A further limitation of our study is the small number
of treated and untreated patients with CTX available
for analyses. In the future, additional samples may be
collected in international consortia like the European
Reference Networks for Rare Neurological Diseases
(ERN-RND; www.ern-rdn.eu) or Metabolic Diseases
(MetabERN; https://metab.ern-net.eu). This would
especially be of interest for longitudinal follow-upMetabolic profiling of patients with CTX 13
studies comparing neurological outcomes to measure-
ments of baseline and posttreatment levels of
oxysterols.
In summary, this comprehensive analysis of meta-
bolic abnormalities in CTX indicates a dichotomic
profile and suggests that quantification of sterol me-
tabolites other than 5α-cholestanol may have increased
utility for diagnosis of CTX. Because oxysterols that are
increased in untreated CTX are substantially reduced
in serum and CSF after CDCA therapy, it is less certain
that elevated levels of toxic metabolites drive the pro-
gression of disease that is observed in some patients
with CTX despite long-term CDCA treatment. In
contrast, the lack of 27-hydroxylated sterol metabolites
is a profound and persisting finding in patients with
CTX before and after treatment with CDCA. This in-
cludes a deficiency of metabolites essential for lipid
import and export in the brain, as well as potentially
neuroprotective compounds. Therefore, we speculate
that a curative approach may require complementation
of 27-hydroxylated metabolites either pharmacologi-
cally or by restoration of sterol 27-hydroxylase activity.
Additional studies are needed to define optimal thera-
peutic strategies for the management of patients with
CTX.
Data availability
Anonymized data from the present study can be
requested for well-defined research questions. Please
contact the corresponding author Ludger Schöls, Uni-
versity Hospital Tübingen, ludger.schoels@uni-
tuebingen.de.
Acknowledgments
The authors heartily thank Stefanie Schuster for her
advice on figure design and helpful discussions of data and
statistics, also they appreciate Yvonne Schelling for her help
with sample management. Anja Kerksiek, Institute of Clin-
ical Chemistry and Clinical Pharmacology, University Hos-
pital Bonn, Bonn, Germany, for GC-MS technical assistance
in analysis of CSF sterols.
L.S., H.H., and F.R. are members of the European Refer-
ence Network for Rare Neurological Diseases—Project ID
No 739510.
Author contributions
L. S. conceptualization; P. H., E. Y., L. G., O. W. H., Y. W., D.
L., W. J. G. methodology; P. M. statistical methodology; P. H.,
P. M. formal analysis; P. H., E. Y., H. H., L. G. investigation; F.
R., S. L. C., P. B. D., A. E. D. resources; P. H., L. S. writing -
original draft; all authors writing - review & editing; P. H.






Owain W. Howell https://orcid.org/0000-0003-2157-915714 J. Lipid Res. (2021) 62 100078Funding and additional information
This work was supported by the Charitable Hertie
Foundation to support the group of L. S. and by the UK
Biotechnology and Biological Sciences Research Council,
grant numbers BB/I001735/1, BB/N015932/1, and BB/
L001942/1.
Conflicts of interest
E. Y. is shareholder in CholesteniX Ltd.; Y. W. is listed as
inventor on the patent Kit and method for quantitative
detection of steroids US9851368B2 and is shareholder in
CholesteniX Ltd.; P. B. D. is consultant at Retrophin and
received an institutional grant from Retrophin; A. E. D. is
consultant for Leadiant Biosciences and Retrophin, institu-
tional grant recipient from Retrophin. The OHSU Foun-
dation and Chemical Physiology and Biology Department
have received gifts from Retrophin. These gifts, which have
not been made specifically in connection with this research,
have been reviewed by the OHSU integrity office; W. J. G. is
listed as inventor on the patent Kit and method for quan-
titative detection of steroids US9851368B2 and is share-
holder in CholesteniX Ltd. All other authors declare that
they have no conflicts of interest with the contents of this
article.
Abbreviations
CTX, cerebrotendinous xanthomatosis; CSF, cerebrospi-
nal fluid; CDCA, chenodeoxycholic acid; LDH, lactate de-
hydrogenase; 7α-HC, 7α-hydroxycholesterol; 7α-HCO, 7α-
hydroxycholest-4-en-3-one; 7α,12α-diHCO, 7α,12α-dihydrox-
ycholest-4-en-3-one; 27-HC, 27-hydroxycholesterol; 7α,25-
diHCO, 7α,25-dihydroxycholest-4-en-3-one.
Manuscript received March 9, 2021, and in revised from
April 13, 2021. Published, JLR Papers in Press, April 20, 2021,
https://doi.org/10.1016/j.jlr.2021.100078
REFERENCES
1. Lv, Bogaert, Scherer, H. J., and Epstein, É. (1937) Une forme
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lipidose à cholestérine). Masson & Cie, Paris, France
2. Salen, G., and Grundy, S. M. (1973) The metabolism of choles-
tanol, cholesterol, and bile acids in cerebrotendinous xantho-
matosis. J. Clin. Invest. 52, 2822–2835
3. Nie, S., Chen, G., Cao, X., and Zhang, Y. (2014) Cerebrotendinous
xanthomatosis: a comprehensive review of pathogenesis, clinical
manifestations, diagnosis, and management. Orphanet J. Rare Dis.
9, 179
4. Cali, J. J., Hsieh, C. L., Francke, U., and Russell, D. W. (1991) Mu-
tations in the bile acid biosynthetic enzyme sterol 27-
hydroxylase underlie cerebrotendinous xanthomatosis. J. Biol.
Chem. 266, 7779–7783
5. Bjorkhem, I., Diczfalusy, U., and Lutjohann, D. (1999) Removal of
cholesterol from extrahepatic sources by oxidative mechanisms.
Curr. Opin. Lipidol. 10, 161–165
6. Björkhem, I., and Hansson, M. (2010) Cerebrotendinous xantho-
matosis: an inborn error in bile acid synthesis with defined
mutations but still a challenge. Biochem. Biophys. Res. Commun. 396,
46–49
7. Berginer, V. M., Salen, G., and Shefer, S. (1984) Long-term
treatment of cerebrotendinous xanthomatosis with cheno-
deoxycholic acid. N. Engl. J. Med. 311, 1649–1652
8. Chiang, J. Y., Kimmel, R., Weinberger, C., and Stroup, D. (2000)
Farnesoid X receptor responds to bile acids and represses
cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J.
Biol. Chem. 275, 10918–10924
9. Duell, P. B., Salen, G., Eichler, F. S., DeBarber, A. E., Connor, S. L.,
Casaday, L., Jayadev, S., Kisanuki, Y., Lekprasert, P., Malloy, M. J.,
Ramdhani, R. A., Ziajka, P. E., Quinn, J. F., Su, K. G., Geller, A. S.,
et al. (2018) Diagnosis, treatment, and clinical outcomes in 43
cases with cerebrotendinous xanthomatosis. J. Clin. Lipidol. 12,
1169–1178
10. Salen, G., Meriwether, T. W., and Nicolau, G. (1975) Cheno-
deoxycholic acid inhibits increased cholesterol and cholestanol
synthesis in patients with cerebrotendinous xanthomatosis. Bio-
chem. Med. 14, 57–74
11. Pilo de la Fuente, B., Sobrido, M. J., Giros, M., Pozo, L., Lustres, M.,
Barrero, F., Macarron, J., Diaz, M., and Jimenez-Escrig, A. (2011)
[Usefulness of cholestanol levels in the diagnosis and follow-up
of patients with cerebrotendinous xanthomatosis]. Neurologia.
26, 397–404
12. Stelten, B. M. L., Huidekoper, H. H., van de Warrenburg, B. P. C.,
Brilstra, E. H., Hollak, C. E. M., Haak, H. R., Kluijtmans, L. A. J.,
Wevers, R. A., and Verrips, A. (2019) Long-term treatment effect
in cerebrotendinous xanthomatosis depends on age at treatment
start. Neurology. 92, e83–e95
13. Bhattacharyya, A. K., Lin, D. S., and Connor, W. E. (2007) Cho-
lestanol metabolism in patients with cerebrotendinous xantho-
matosis: absorption, turnover, and tissue deposition. J. Lipid Res.
48, 185–192
14. Crick, P. J., Bentley, T. W., Wang, Y., and Griffiths, W. J. (2015)
Revised sample preparation for the analysis of oxysterols by
enzyme-assisted derivatisation for sterol analysis (EADSA). Anal.
Bioanal. Chem. 407, 5235–5239
15. Crick, P. J., William Bentley, T., Abdel-Khalik, J., Matthews, I.,
Clayton, P. T., Morris, A. A., Bigger, B. W., Zerbinati, C., Trita-
pepe, L., Iuliano, L., Wang, Y., and Griffiths, W. J. (2015) Quan-
titative charge-tags for sterol and oxysterol analysis. Clin. Chem.
61, 400–411
16. Griffiths, W. J., Crick, P. J., Wang, Y., Ogundare, M., Tuschl, K.,
Morris, A. A., Bigger, B. W., Clayton, P. T., and Wang, Y. (2013)
Analytical strategies for characterization of oxysterol lipidomes:
liver X receptor ligands in plasma. Free Radic. Biol. Med. 59, 69–84
17. Griffiths, W. J., Crick, P. J., Meljon, A., Theofilopoulos, S., Abdel-
Khalik, J., Yutuc, E., Parker, J. E., Kelly, D. E., Kelly, S. L., Arenas,
E., and Wang, Y. (2019) Additional pathways of sterol meta-
bolism: Evidence from analysis of Cyp27a1-/- mouse brain and
plasma. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 1864, 191–211
18. Mackay, D. S., Jones, P. J., Myrie, S. B., Plat, J., and Lutjohann, D.
(2014) Methodological considerations for the harmonization of
non-cholesterol sterol bio-analysis. J. Chromatogr. B Analyt. Technol.
Biomed. Life Sci. 957, 116–122
19. Popp, J., Lewczuk, P., Kölsch, H., Meichsner, S., Maier, W., Korn-
huber, J., Jessen, F., and Lütjohann, D. (2012) Cholesterol meta-
bolism is associated with soluble amyloid precursor protein
production in Alzheimer's disease. J. Neurochem. 123, 310–316
20. Smith, L. P., Nierstenhoefer, M., Yoo, S. W., Penzias, A. S.,
Tobiasch, E., and Usheva, A. (2009) The bile acid synthesis
pathway is present and functional in the human ovary. PLoS One.
4, e7333
21. Theofilopoulos, S., Griffiths, W. J., Crick, P. J., Yang, S., Meljon, A.,
Ogundare, M., Kitambi, S. S., Lockhart, A., Tuschl, K., Clayton, P.
T., Morris, A. A., Martinez, A., Reddy, M. A., Martinuzzi, A., Bassi,
M. T., et al. (2014) Cholestenoic acids regulate motor neuron
survival via liver X receptors. J. Clin. Invest. 124, 4829–4842
22. Meaney, S., Heverin, M., Panzenboeck, U., Ekstrom, L., Axelsson,
M., Andersson, U., Diczfalusy, U., Pikuleva, I., Wahren, J., Sattler,
W., and Bjorkhem, I. (2007) Novel route for elimination of brain
oxysterols across the blood-brain barrier: conversion into
7alpha-hydroxy-3-oxo-4-cholestenoic acid. J. Lipid Res. 48,
944–951
23. Duane, W. C., Bjorkhem, I., Hamilton, J. N., and Mueller, S. M.
(1988) Quantitative importance of the 25-hydroxylation
pathway for bile acid biosynthesis in the rat.Hepatology. 8, 613–61824. Batta, A. K., Salen, G., Shefer, S., Tint, G. S., and Batta, M. (1987)
Increased plasma bile alcohol glucuronides in patients with
cerebrotendinous xanthomatosis: effect of chenodeoxycholic
acid. J. Lipid Res. 28, 1006–1012
25. Vaz, F. M., Bootsma, A. H., Kulik, W., Verrips, A., Wevers, R. A.,
Schielen, P. C., DeBarber, A. E., and Huidekoper, H. H. (2017)
A newborn screening method for cerebrotendinous xantho-
matosis using bile alcohol glucuronides and metabolite ratios. J.
Lipid Res. 58, 1002–1007
26. Schols, L., Rattay, T. W., Martus, P., Meisner, C., Baets, J., Fischer,
I., Jagle, C., Fraidakis, M. J., Martinuzzi, A., Saute, J. A., Scarlato,
M., Antenora, A., Stendel, C., Hoflinger, P., Lourenco, C. M., et al.
(2017) Hereditary spastic paraplegia type 5: natural history,
biomarkers and a randomized controlled trial. Brain. 140,
3112–3127
27. Berginer, V. M., Salen, G., and Patel, S. B. (2015) Cere-
brotendinous Xanthomatosis. In Rosenberg's Molecular and Genetic
Basis of Neurological and Psychiatric Disease. R. N. Rosenberg and J.
M. Pascual, editors. Academic Press, Boston, MA, 589–598
28. Bavner, A., Shafaati, M., Hansson, M., Olin, M., Shpitzen, S.,
Meiner, V., Leitersdorf, E., and Bjorkhem, I. (2010) On the
mechanism of accumulation of cholestanol in the brain of mice
with a disruption of sterol 27-hydroxylase. J. Lipid Res. 51,
2722–2730
29. Uhlen, M., Fagerberg, L., Hallstrom, B. M., Lindskog, C., Oksvold,
P., Mardinoglu, A., Sivertsson, A., Kampf, C., Sjostedt, E.,
Asplund, A., Olsson, I., Edlund, K., Lundberg, E., Navani, S., Szi-
gyarto, C. A., et al. (2015) Proteomics. Tissue-based map of the
human proteome. Science. 347, 1260419
30. Chiang, J. Y. (2004) Regulation of bile acid synthesis: pathways,
nuclear receptors, and mechanisms. J. Hepatol. 40, 539–551
31. Ellis, E., Axelson, M., Abrahamsson, A., Eggertsen, G., Thörne, A.,
Nowak, G., Ericzon, B-G., Björkhem, I., and Einarsson, C. (2003)
Feedback regulation of bile acid synthesis in primary human
hepatocytes: evidence that CDCA is the strongest inhibitor.
Hepatology. 38, 930–938
32. Heverin, M., Meaney, S., Lutjohann, D., Diczfalusy, U., Wahren, J.,
and Bjorkhem, I. (2005) Crossing the barrier: net flux of 27-
hydroxycholesterol into the human brain. J. Lipid Res. 46,
1047–1052
33. Li, D., Long, W., Huang, R., Chen, Y., and Xia, M. (2018) 27-
Hydroxycholesterol Inhibits Sterol Regulatory Element-
Binding Protein 1 Activation and Hepatic Lipid Accumulation
in Mice. Obesity (Silver Spring). 26, 713–722
34. Radhakrishnan, A., Ikeda, Y., Kwon, H. J., Brown, M. S., and
Goldstein, J. L. (2007) Sterol-regulated transport of SREBPs
from endoplasmic reticulum to Golgi: oxysterols block trans-
port by binding to Insig. Proc. Natl. Acad. Sci. U.S.A. 104,
6511–6518
35. Kim, W. S., Chan, S. L., Hill, A. F., Guillemin, G. J., and Garner, B.
(2009) Impact of 27-hydroxycholesterol on amyloid-beta pep-
tide production and ATP-binding cassette transporter expres-
sion in primary human neurons. J. Alzheimers Dis. 16, 121–131
36. Piguet, F., Alves, S., and Cartier, N. (2017) Clinical Gene Therapy
for Neurodegenerative Diseases: Past, Present, and Future. Hum.
Gene Ther. 28, 988–1003
37. Lutjohann, D., Stellaard, F., and Bjorkhem, I. (2020) Levels of
7alpha-hydroxycholesterol and/or 7alpha-hydroxy-4-cholest-3-
one are the optimal biochemical markers for the evaluation of
treatment of cerebrotendinous xanthomatosis. J. Neurol. 267,
572–573
38. DeBarber, A. E., Luo, J., Giugliani, R., Souza, C. F., Chiang, J. P.,
Merkens, L. S., Pappu, A. S., and Steiner, R. D. (2014) A useful
multi-analyte blood test for cerebrotendinous xanthomatosis.
Clin. Biochem. 47, 860–863
39. Bindl, L., Lutjohann, D., Lentze, M. J., and von Bergmann, K.
(2001) Cerebrotendinous xanthomatosis presenting as "cholo-
genic diarrhoea". Acta Paediatr. 90, 828–829Metabolic profiling of patients with CTX 15
